Scientus Pharma Obtains Health Canada Approval for Sale of Cannabis Oils and Capsules

 HydRx Farms Ltd. announced it has received its Oils and Capsules Sales License from Health Canada pursuant to the Cannabis Act and its Regulations.

This License to sell oils and capsules, effective May 24, 2019, is the latest approval in a series of licensing achievements for Scientus Pharma and comes on the heels of the oils and capsules Production License granted by Health Canada in October 2018. Scientus Pharma is also licensed to both produce and sell dried cannabis.  

“Obtaining approval to sell cannabis oils and capsules is one of our most significant milestones to date,” said Har Grover, Chairman and CEO of Scientus Pharma. “It is critical to our strategy of commercializing cannabis derivatives that are manufactured using our ground-breaking, patented extraction technology.”

Scientus Pharma’s patented technology platform enables it to consistently achieve >99.5% activation of the cannabinoids (a process known as decarboxylation). This level of decarboxylation is in contrast to the range of values currently achieved using the industry-standard extraction processes (between 0-95% decarboxylation).

“We’re delivering a superior medical cannabis product, so patients and Health Care Providers can be confident that they are getting the same predictable outcome with every capsule,” commented Mr. Grover.

Scientus Pharma’s fully decarboxylated oils and capsules, branded Medisenol, will begin shipping in 4-6 weeks. To sign up for the Medisenol waitlist, please visit www.medisenol.com.